Abbvie Inc (ABBV)

$231.50 +4.00 (1.76%)
Market Cap 409.15B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.75
Forward PE 15.58
Profit Margin 6.91%
Debt to Equity Ratio -26.45
Volume 8,252,400
Avg Vol 6,627,614
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 89%
Beta 0.35
Analysts Strong Sell
Price Target $245.60

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
ern1in
ern1in Feb. 15 at 5:10 PM
$ABBV 🦬
0 · Reply
maikl_211
maikl_211 Feb. 15 at 9:32 AM
$COST $NFLX $BAC $ABBV $MU
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 14 at 8:33 PM
$TNXP $AXSM $VRTX $ABBV well if you ask ChatGPT for the best analog to Tonmya from Tonix, it’s Auvelity from Axsome - fitting given they’re also developing a fibromyalgia drug, but a much different space. I went back and dug up CNS comparators- Tonmya is doing just as well! The chart for all in the first 10 weeks of sales looks similar (capture rate in Symphony is quite low as discussed - and samples/ “free drug” are also not included). The market makers saw the dip in sales due to the crazy winter storm and sold. The wise were buying and holding long. The next year is key, but Tonmya is on a blockbuster path when compared to other recent CNS launches. Tonmya will be a Juggernaut for fibromyalgia patients to start, and Tonix may need to fight off some buyouts if the stock stays this low 🚀 Vertex, Otsuka, AbbVie, even BMY could all buy them out 🏦 FYI @Night_Owl_Biotech @Proposition_Joe @Hoppanin @PeteyUSA @BioCapitalist99 @Duediligence20
2 · Reply
DennBillions
DennBillions Feb. 13 at 11:36 PM
$ABBV
0 · Reply
middleman
middleman Feb. 13 at 9:55 PM
$ABBV this is still one of my favorites, never disappoints
0 · Reply
KCclean
KCclean Feb. 13 at 6:44 PM
$ABBV interesting spot here on the weekly from my view (crappy phone chart)
0 · Reply
usiv
usiv Feb. 13 at 5:00 PM
$ABBV nice move
0 · Reply
TruthBroker2
TruthBroker2 Feb. 13 at 3:13 PM
$ABBV $PLSE $SMMT $ISRG
0 · Reply
usiv
usiv Feb. 13 at 2:48 PM
$ABBV need to close above that downtrend line
0 · Reply
xtremdelt8
xtremdelt8 Feb. 13 at 2:31 PM
$ABBV
0 · Reply
Latest News on ABBV
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 13, 2026, 12:57 PM EST - 2 days ago

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

Feb 12, 2026, 7:30 AM EST - 4 days ago

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

AM APH AR ASML AVAV BTU CARR

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 4 days ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 4 days ago

Abbvie sues US health agency over Botox

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 4 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE

Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 6 days ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO

AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 11 days ago

AbbVie: The Market Is Getting It Wrong

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

Feb 5, 2026, 4:25 AM EST - 11 days ago

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

Feb 4, 2026, 6:04 PM EST - 11 days ago

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

Feb 4, 2026, 5:45 PM EST - 11 days ago

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

Feb 4, 2026, 3:39 PM EST - 11 days ago

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 11 days ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 12:38 PM EST - 12 days ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 12 days ago

AbbVie Revenue Rises on Immunology Growth

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 8:18 AM EST - 12 days ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:51 AM EST - 12 days ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 4, 2026, 7:48 AM EST - 12 days ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:50 AM EST - 13 days ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Feb 3, 2026, 8:00 AM EST - 13 days ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Jan 29, 2026, 10:30 PM EST - 17 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

10 Highest Rated Dividend Kings For Generations Of Income

Jan 29, 2026, 10:10 AM EST - 18 days ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 29, 2026, 8:00 AM EST - 18 days ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 28, 2026, 8:00 AM EST - 19 days ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 19 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 27, 2026, 9:34 AM EST - 20 days ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 21 days ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:43 PM EST - 4 weeks ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Jan 16, 2026, 1:35 PM EST - 4 weeks ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 5:45 PM EST - 4 weeks ago

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AbbVie plans to build out its presence in obesity market

Jan 14, 2026, 2:01 PM EST - 4 weeks ago

AbbVie plans to build out its presence in obesity market

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 7:22 AM EST - 4 weeks ago

AbbVie reaches 3-year deal with White House to lower drug prices

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 13, 2026, 5:24 AM EST - 4 weeks ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 7:03 PM EST - 4 weeks ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:57 PM EST - 4 weeks ago

Abbvie, US reach agreement to cut drug prices

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 6:30 PM EST - 4 weeks ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:39 AM EST - 5 weeks ago

AbbVie, RemeGen partner on experimental solid tumor treatment

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 7:30 AM EST - 5 weeks ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

Jan 12, 2026, 6:00 AM EST - 5 weeks ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

Jan 12, 2026, 6:00 AM EST - 5 weeks ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Dividend Income: Lanny's November 2025 Summary

Jan 12, 2026, 5:12 AM EST - 5 weeks ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

MoneyShow's Best Investment Ideas For 2026: Part 1

Jan 10, 2026, 9:30 AM EST - 5 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 12:07 PM EST - 5 weeks ago

AbbVie: The Dividend Does Not Lie

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

Jan 8, 2026, 7:38 AM EST - 5 weeks ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

Jan 7, 2026, 2:58 PM EST - 5 weeks ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

AbbVie Near Deal for Revolution Medicines

Jan 7, 2026, 2:48 PM EST - 5 weeks ago

AbbVie Near Deal for Revolution Medicines

RVMD

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 7, 2026, 8:00 AM EST - 5 weeks ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 11:43 AM EST - 5 weeks ago

What Can Trigger A Breakout In Abbvie Stock?

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Jan 6, 2026, 7:29 AM EST - 5 weeks ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 6 weeks ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 4, 2026, 9:04 AM EST - 6 weeks ago

AbbVie: Rocky Near-Term, Positive Long-Term

ern1in
ern1in Feb. 15 at 5:10 PM
$ABBV 🦬
0 · Reply
maikl_211
maikl_211 Feb. 15 at 9:32 AM
$COST $NFLX $BAC $ABBV $MU
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 14 at 8:33 PM
$TNXP $AXSM $VRTX $ABBV well if you ask ChatGPT for the best analog to Tonmya from Tonix, it’s Auvelity from Axsome - fitting given they’re also developing a fibromyalgia drug, but a much different space. I went back and dug up CNS comparators- Tonmya is doing just as well! The chart for all in the first 10 weeks of sales looks similar (capture rate in Symphony is quite low as discussed - and samples/ “free drug” are also not included). The market makers saw the dip in sales due to the crazy winter storm and sold. The wise were buying and holding long. The next year is key, but Tonmya is on a blockbuster path when compared to other recent CNS launches. Tonmya will be a Juggernaut for fibromyalgia patients to start, and Tonix may need to fight off some buyouts if the stock stays this low 🚀 Vertex, Otsuka, AbbVie, even BMY could all buy them out 🏦 FYI @Night_Owl_Biotech @Proposition_Joe @Hoppanin @PeteyUSA @BioCapitalist99 @Duediligence20
2 · Reply
DennBillions
DennBillions Feb. 13 at 11:36 PM
$ABBV
0 · Reply
middleman
middleman Feb. 13 at 9:55 PM
$ABBV this is still one of my favorites, never disappoints
0 · Reply
KCclean
KCclean Feb. 13 at 6:44 PM
$ABBV interesting spot here on the weekly from my view (crappy phone chart)
0 · Reply
usiv
usiv Feb. 13 at 5:00 PM
$ABBV nice move
0 · Reply
TruthBroker2
TruthBroker2 Feb. 13 at 3:13 PM
$ABBV $PLSE $SMMT $ISRG
0 · Reply
usiv
usiv Feb. 13 at 2:48 PM
$ABBV need to close above that downtrend line
0 · Reply
xtremdelt8
xtremdelt8 Feb. 13 at 2:31 PM
$ABBV
0 · Reply
trading_momentum_x
trading_momentum_x Feb. 13 at 11:04 AM
$ABBV just ripping. Posted about this in investments channel in 2024 when it was 130s. Great dividend growth stock in the healthcare sector.
0 · Reply
JFDI
JFDI Feb. 12 at 11:56 PM
$ABBV
0 · Reply
RunnerSignals
RunnerSignals Feb. 12 at 9:50 PM
Top stock upgrades today in the BUZZ $ABBV $AMAT $ANET $APP $COIN showing momentum! https://stocksrunner.com/news/2026-02-12-top-stock-upgrades-today-in-the-buzz
0 · Reply
HedgeFollow
HedgeFollow Feb. 12 at 8:13 PM
🚨BLACKROCK Q4 portfolio just released! Notable Trades: - Reduced $SNDK & $MA - Added $ABBV, $AMD & $META Source: https://hedgefollow.com/funds/BlackRock
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 12 at 7:16 PM
$SLS $ABBV Little Known Fact: REGAL Excludes AML Patients with targetable Mutations, like IDH1/2 - Ivosidenib, Olutasidenib, Enasidenib. Aza +VEN is most Effective for IDH1/2 Patients, who ARE NOT EVEN ALLOWED IN THE SLS REGAL PHASE 3... https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27246 Once you Exclude the IDH1/2 Patients from The VIALE-A MOS - it is only 10.3 months for FRONT LINE / NEWLY DIAGNOSED AML Patients. ///
0 · Reply
OffHisGame88
OffHisGame88 Feb. 12 at 6:59 PM
$ABBV safe pharma companies good for next 3 months $MRK $JNJ top 3
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 12 at 6:46 PM
$SLS $ABBV https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27246 Aza+VEN Adverse Events 100% of Patients, 99% grade 3 or Higher 25% of the Patients taking Aza+VEN Died From taking Aza+VEN. - You Know BAT is not the reason. - BAT / AZA+VEN is not an effective treatment for AML Patients Getting into a Second Remission, and are Transplant INELIGIBLE. -- just like the 3 Doctors, who treat 15% of the REGAL Phase 3 Patients have stated.
0 · Reply
SAS080
SAS080 Feb. 12 at 6:38 PM
$ABBV 300% sold.. all out!!!
0 · Reply
Big_Daddy_21
Big_Daddy_21 Feb. 12 at 4:49 PM
I’ll take boring all day. $KR $ABBV
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 12 at 4:18 PM
$SLS $ABBV The Initial VIALE-A Side Effects ~ 23% Died from Taking Aza+VEN ~ 83% Serious Events vs long term Follow up at ~ 25% Died from Taking Aza+VEN 85% SA's Importantly - No Trials have Ever Confirmed VIALE-A Results AND VIALE-T FAILED, and VIALE-M FAILED. BAT FAILED the SLS REGAL PHASE 3 Control Patients Too.
1 · Reply
HydrogenH2
HydrogenH2 Feb. 12 at 3:53 PM
$ABBV AbbVie files a federal lawsuit against the U.S. Department of Health and Human Services and CMS seeking to block Medicare price controls on Botox under the Inflation Reduction Act, arguing the drug is exempt as a plasma-derived product. Really ?? JRK will need some Tylenol...!! But i will take some profits...for now !! I bought @ earnings @ $208-$210 Thanks !!
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 12 at 3:49 PM
$SLS $ABBV TEAEs led to death in 71/283 patients (25%) in the venetoclax-azacitidine arm 25% of the Patients Taking Aza+VEN DIED From Taking Aza+VEN Aza+VEN - BAT for the SLS REGAL Phase 3 Control Arm is dangerous, and deadly toxcic. Meanwhile, we are Seeing Near Miraculous, ALL POOLED Survival - all pooled: Control on BAT + Gps Patients combined. Hello??
0 · Reply